Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

17.90 +0.51 (+2.93%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,685,179
Open	17.39
Bid (Size)	17.41 (2,000)
Ask (Size)	18.25 (200)
Prev. Close	17.39
Today's Range	17.38 - 18.38
52wk Range	13.18 - 34.29
Shares Outstanding	9,587,155
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 27, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.

Via The Motley Fool

Performance

YTD	-41.7%	-41.7%
1 Month	+5.3%	+5.3%
3 Month	-36.5%	-36.5%
6 Month	-43.9%	-43.9%
1 Year	+21.8%	+21.8%

More News

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

May 06, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

May 05, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Which stocks are gapping on Tuesday? ↗

May 05, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

May 05, 2026

Via Chartmill

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 05, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

May 05, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know ↗

April 21, 2026

Via The Motley Fool

Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment

April 13, 2026

Via MarketMinute

Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data

April 09, 2026

Via MarketMinute

Which stocks are moving on Monday? ↗

April 06, 2026

Via Chartmill

Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones

April 02, 2026

Via MarketMinute

Which stocks are experiencing notable movement on Monday? ↗

March 30, 2026

Via Chartmill

Here are the top movers in Monday's session. ↗

March 30, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Monday's session. ↗

March 30, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 30, 2026

Via Chartmill

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

March 30, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Viridian Therapeutics, Inc. - Common Stock publicly traded?

Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?

Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?

The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market

What is the current price of Viridian Therapeutics, Inc. - Common Stock?

The current price of Viridian Therapeutics, Inc. - Common Stock is 17.90

When was Viridian Therapeutics, Inc. - Common Stock last traded?

The last trade of Viridian Therapeutics, Inc. - Common Stock was at 06/26/26 04:00 PM ET

What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?

The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 171.61M

How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?

Viridian Therapeutics, Inc. - Common Stock has 172M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.